IRADIMED Business Summary

IRADIMED CORP (IRMD) operates a high-margin medical technology business model centered on the development and sale of non-magnetic, MRI-compatible medical devices. The company generates revenue through three primary segments: MRI-compatible intravenous (IV) infusion pump systems, patient vital signs monitoring systems, and a recurring stream of high-margin disposables and maintenance services. As of early 2026, the company is executing a major product transition with the full-scale rollout of its next-generation 3870 infusion pump, targeting a domestic replacement market of over 6,400 legacy channels. IRADIMED maintains a dominant niche position with gross margins near 77%, distinguishing itself from broader medical equipment peers like Envista (NVST), iRhythm Technologies (IRTC), and LivaNova (LIVN) by specializing exclusively in the technically demanding interference-free MRI environment. The leadership team is anchored by Founder, President, and CEO Roger Susi, a biomedical engineer and pioneer in the field who previously founded Invivo Research Inc., the company that established the first MRI-safe patient monitoring standards. Supporting Susi are Chief Financial Officer John “Jack” Glenn, who joined in 2022 with over 30 years of financial executive experience, and Chief Commercial Officer Jeff Chiprin, a medtech veteran appointed in late 2024 to lead global sales strategies. The company’s governance was significantly bolstered in September 2025 with the appointment of Joe Kiani, the founder and former CEO of Masimo, to the Board of Directors. Other notable board members include Hilda Scharen-Guivel, a former FDA Program Director, and James Hawkins, the former CEO of Natus Medical, providing the firm with deep regulatory and operational expertise.